Merck's Keytruda for Most Common Form of Lung Cancer Approved

by Vishnuprasad on  October 3, 2015 at 6:23 PM Drug News
RSS Email Print This Page Comment
The U.S. Food and Drug Administration approved Merck & Co.'s Keytruda for the treatment of the most common form of lung cancer.
Merck's Keytruda for Most Common Form of Lung Cancer Approved
Merck's Keytruda for Most Common Form of Lung Cancer Approved
Advertisement

Keytruda can be used in patients with non-small-cell lung cancer whose tumors contain a certain level of a protein known as PD-L1, and whose disease continued to worsen after the patient received chemotherapy or other drugs.

Advertisement
The regulator also approved a companion diagnostic developed by Dako North America Inc. to test for PD-L1, to screen for patients who should receive Merck's Keytruda.

A study found that Keytruda worked better in lung-cancer patients with higher levels of PD-L1 than in patients with lower or undetectable levels.

Merck estimates roughly 25% of all non-small-cell lung-cancer patients have PD-L1 levels that would make them eligible for Keytruda treatment.



Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Lung Biopsy Lung Cancer Malignant Mesothelioma Cancer and Homeopathy Cancer Facts Asbestosis Cancer Tattoos A Body Art Pneumoconiosis Smoking among Women 
Advertisement

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Advertisement
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive